Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tetraphase's Broad Spectrum Antibiotic Xerava Priced To Move

Related Content

OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No

Jul 27 2018

Actavis’ <em>Avycaz</em> Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic

Mar 02 2015

Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms

May 17 2017

Cubist wins FDA nod for antibiotic Zerbaxa

Dec 20 2014

Another Antibiotic Success Story as Tetraphase's Eravacycline Meets Goal

Jul 26 2017

Related Companies

Tetraphase Pharmaceuticals, Inc.

Merck & Co., Inc.

Allergan plc

Additional Topics

Approvals Launches Pricing Strategies Infectious Diseases BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window